metaEvidence COVID-19 - living meta-analysis

button bars forest bayes pooled summary circles

Treament	Trials
Treament	Trials	Statistically conclusive or suggested result	Inconclusive results	Uncertain results	Safety results
study description meta-analysis results	9	suggested 97 % decrease in confirmed COVID (any severity) statistically conclusive 92 % decrease in symptomatic Covid-19	inconclusive results for: deaths; serious adverse events; adverse events; convulsions/seizures ; disseminated intravascular coagulation ; Guillain-Barré syndrome ; immune thrombocytopenia ; ischemic stroke; Myocardial infarction ; myocarditis; pericarditis ; pulmonary embolism; Transverse myelitis ; venous thromboembolism ; VTE with thrombocytopenia; cerebral venous sinus thrombosis (CVST); arthralgia, grade 3-4; Bell's palsy; hypersensitivity, all terms; lymphadenopathy, grade 3-4; musculoskeletal and connective tissue disorders, any; myalgia, grade 3-4; fever, grade 3-4; local adverse reaction, any, dose 2; local adverse reaction, grade 3-4, dose 2; systemic adverse reaction, any, dose 2; systemic adverse reaction, grade 3-4, dose 2	suggested 95 % decrease in confirmed Covid-19, from 1st dose but the degree if certainty is unassessable suggested 59 % decrease in death D28 but the degree if certainty is unassessable suggested 93 % decrease in vaccine efficacy from randomization (ITT) but the degree if certainty is unassessable statistically conclusive 98 % decrease in severe COVID-19 occurrence but the degree if certainty is unassessable suggested 18 % decrease in appendicitis but with a very low degree of certainty due to critical risk of bias	-
study description meta-analysis results	39	suggested 83 % decrease in confirmed Covid-19, from 1st dose suggested 90 % decrease in confirmed COVID (any severity) suggested 71 % decrease in vaccine efficacy after dose 1 (and before dose 2)	inconclusive results for: deaths; cerebrovascular thromboembolic events; related AE (TRAE); related SAE (TRSAE); serious adverse events; adverse events; arrhythmia; Arthritis or arthropathy ; convulsions/seizures ; deep vein thrombosis; disseminated intravascular coagulation ; Guillain-Barré syndrome ; Herpes simplex infection ; herpes zoster infection ; immune thrombocytopenia ; intracranial hemorrhage ; ischemic stroke; life-threatening SAE; Myocardial infarction ; myocarditis; neutropenia ; paresthesia ; pericarditis ; pulmonary embolism; severe adverse events; thrombocytopenia ; Transverse myelitis ; uveitis ; venous thromboembolism ; VTE with thrombocytopenia; cerebral venous sinus thrombosis (CVST); appendicitis; Bell's palsy; hypersensitivity, all terms; immediate allergic reaction; lymphadenopathy, any; musculoskeletal and connective tissue disorders, any; myelitis; local adverse reaction, any, dose 1; local adverse reaction, any, dose 2; systemic adverse reaction, any, dose 1; systemic adverse reaction, any, dose 2	suggested 91 % decrease in 6 months symptomatic COVID but the degree if certainty is unassessable suggested 82 % decrease in vaccine efficacy from randomization (ITT) but the degree if certainty is unassessable suggested 92 % decrease in hospitalization but the degree if certainty is unassessable statistically conclusive 94 % decrease in symptomatic Covid-19 but the degree if certainty is unassessable suggested 97 % decrease in 6 months severe COVID-19 but the degree if certainty is unassessable suggested 77 % decrease in asymptomatic COVID case but the degree if certainty is unassessable suggested 83 % decrease in infection (PCR positive symptomatic or not) but the degree if certainty is unassessable suggested 94 % decrease in severe COVID-19 occurrence but the degree if certainty is unassessable suggested 47 % decrease in transmission (symptomatic confirmed COVID19) but with a low degree of certainty due to high risk of bias suggested 56 % decrease in acute kidney injury but the degree if certainty is unassessable suggested 21 % decrease in Anemia but the degree if certainty is unassessable	-
study description meta-analysis results	19	statistically conclusive 71 % decrease in symptomatic Covid-19 suggested 85 % decrease in vaccine efficacy after dose 1 (and before dose 2)	inconclusive results for: deaths; severe COVID-19 occurrence; serious adverse events; adverse events; ATE (Myocardial infarction or ischemic stroke); ATE with thrombocytopenia; deep vein thrombosis; disseminated intravascular coagulation ; Guillain-Barré syndrome ; immune thrombocytopenia ; intracranial hemorrhage ; ischemic stroke; Myocardial infarction ; pulmonary embolism; serious adverse events (SAE), any; splanchnic vein thrombosis (SVT); stroke (non-specific, hemorrhagic, and ischemic); stroke with thrombocytopenia; thrombocytopenia ; venous thromboembolism ; VTE with thrombocytopenia; cerebral venous sinus thrombosis (CVST); Bell's palsy; immediate allergic reaction; multiple sclerosis; myelitis; Potential Immune Gastrointestinal disorders; Potential Immune Musculoskeletal disorders; Potential Immune Neuroinflammatory disorders; Potential Immune Skin disorders; Potential Immune Vasculitides; Thromboembolic events	suggested 67 % decrease in asymptomatic COVID case but the degree if certainty is unassessable suggested 56 % decrease in infection (PCR positive symptomatic or not) but the degree if certainty is unassessable suggested 48 % decrease in transmission (symptomatic confirmed COVID19) but with a low degree of certainty due to high risk of bias	-
study description meta-analysis results	9	none	inconclusive results for: hospitalization; ATE (Myocardial infarction or ischemic stroke); deep vein thrombosis; Guillain-Barré syndrome ; intracranial hemorrhage ; ischemic stroke; Myocardial infarction ; myocarditis; pericarditis ; pulmonary embolism; venous thromboembolism ; cerebral venous sinus thrombosis (CVST); appendicitis; Bell's palsy	suggested 81 % decrease in deaths but the degree if certainty is unassessable statistically conclusive 67 % decrease in symptomatic Covid-19 but the degree if certainty is unassessable suggested 77 % decrease in severe COVID-19 occurrence but the degree if certainty is unassessable	-
study description meta-analysis results	62	suggested 88 % decrease in confirmed Covid-19, from 1st dose suggested 82 % decrease in deaths suggested 89 % decrease in vaccine efficacy from randomization (ITT) suggested 93 % decrease in confirmed COVID (any severity) suggested 70 % decrease in vaccine efficacy after dose 1 (and before dose 2)	inconclusive results for: cerebrovascular thromboembolic events; related AE (TRAE); related SAE (TRSAE); serious adverse events; adverse events; arrhythmia; Arthritis or arthropathy ; convulsions/seizures ; deep vein thrombosis; disseminated intravascular coagulation ; Guillain-Barré syndrome ; Herpes simplex infection ; herpes zoster infection ; immune thrombocytopenia ; intracranial hemorrhage ; ischemic stroke; life-threatening SAE; Myocardial infarction ; myocarditis; neutropenia ; paresthesia ; pericarditis ; pulmonary embolism; severe adverse events; thrombocytopenia ; Transverse myelitis ; uveitis ; venous thromboembolism ; VTE with thrombocytopenia; cerebral venous sinus thrombosis (CVST); appendicitis; arthralgia, grade 3-4; Bell's palsy; hypersensitivity, all terms; immediate allergic reaction; lymphadenopathy, any; lymphadenopathy, grade 3-4; musculoskeletal and connective tissue disorders, any; myalgia, grade 3-4; myelitis; fever, grade 3-4; local adverse reaction, any, dose 1; local adverse reaction, any, dose 2; local adverse reaction, grade 3-4, dose 2; systemic adverse reaction, any, dose 1; systemic adverse reaction, any, dose 2; systemic adverse reaction, grade 3-4, dose 2	suggested 91 % decrease in 6 months symptomatic COVID but the degree if certainty is unassessable suggested 59 % decrease in death D28 but the degree if certainty is unassessable suggested 92 % decrease in hospitalization but the degree if certainty is unassessable statistically conclusive 93 % decrease in symptomatic Covid-19 but the degree if certainty is unassessable suggested 97 % decrease in 6 months severe COVID-19 but the degree if certainty is unassessable suggested 77 % decrease in asymptomatic COVID case but the degree if certainty is unassessable suggested 83 % decrease in infection (PCR positive symptomatic or not) but the degree if certainty is unassessable statistically conclusive 94 % decrease in severe COVID-19 occurrence but the degree if certainty is unassessable suggested 47 % decrease in transmission (symptomatic confirmed COVID19) but with a low degree of certainty due to high risk of bias suggested 56 % decrease in acute kidney injury but the degree if certainty is unassessable suggested 21 % decrease in Anemia but the degree if certainty is unassessable	-

Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant

Living meta-analysis and evidence synthesis of therapies for COVID19